Reaktionsgleichung
[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[N:9]1[CH2:14][CH2:13][N:12]([CH2:15][CH2:16][CH2:17][C:18]([O:20][CH2:21][C:22]2[CH:31]=[C:30]3[C:25]([CH2:26][CH2:27][C:28](=[O:32])[NH:29]3)=[CH:24][CH:23]=2)=[O:19])[CH2:11][CH2:10]1.[ClH:33]>>[ClH:33].[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[N:9]1[CH2:10][CH2:11][N:12]([CH2:15][CH2:16][CH2:17][C:18]([O:20][CH2:21][C:22]2[CH:31]=[C:30]3[C:25]([CH2:26][CH2:27][C:28](=[O:32])[NH:29]3)=[CH:24][CH:23]=2)=[O:19])[CH2:13][CH2:14]1Komponenten
3
Versuchsvorschrift
(2-Oxo-1,2,3,4-tetrahydroquinolin-7-yl)methyl 4-(4-(2-methoxyphenyl)piperazin-1-yl)butanoate hydrochloride (39c) (Scheme 7) was prepared from the compound 38c according to the protocol described for the compound 39a (Example 49). The hydrochloride salt 39c gave satisfactory 1H NMR spectral data. White solid, 0.05 g (31%). MS (ESI): m/z=438.2 (M+H+).
Quellen und Nachweise
- ORD-Eintrag
- ord-9c24b41c907a4a5386e87c2ab9273e29
- Quelldatensatz
- uspto-grants-2012_08
- Patentnummer
- US08247420B2
Verknüpfte Notizen
Wird geladen…